Shares of small cap clinical-stage vaccine company Novavax, Inc. NVAX have lost more than 14.5 percent since the beginning of the year. However, since mid-May lows, the stock has managed to recuperate more than 65.5 percent of its value.
Nonetheless, the Vetr crowd seems to believe there is still room for upside left, as evidenced by its average price target of $8.66. This implies a potential return of more than 14.6 percent from current valuations.
Related Link: Here's How Crowdsourced Ratings Can Beat The Market
Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Novavax on Wednesday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) - out of a possible 5.0 Stars rating.
It should be noted that, in accordance with the new rating, 71 percent of the crowd’s ratings are bullish.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
